
Kidney doc, biochemist, and dad, taking life one kinesin-sized step at a time. He/him. @VertexPharma | @BIDMChealth | @nufeinbergmed | opinions my own
Boston, MA
Joined July 2009
- Tweets7.9K
- Following3.3K
- Followers3.1K
- Likes21.2K
Pinned Tweet
Some say that being a physician-scientist is like wearing two hats.
I think it lets me #sockittokidneydisease in two different ways.
One foot is in the clinic, helping patients get the best treatments.
The other is in the lab, trying to make those treatments better.
Joshua Waitzman, MD PhD retweeted
I am honored and thrilled to take this next step, and hope to live up to the impressive leadership of my mentors Roger Brumback and Marc Patterson.
We are delighted to announce that Alison Christy, MD, PhD, will be stepping into the role of Editor-in-Chief of the Journal of Child Neurology in January 2025. We look forward to a bright future for our journal! @OligoclonalBand
Joshua Waitzman, MD PhD retweeted
Are you ready for @VCU_Nephrology MS2 Renal meme competition? @MemesNephro @VCUIMClerkship @VCU_IMRes
1. 'Fall's formula' by David Hutton
Joshua Waitzman, MD PhD retweeted
I truly do not think anybody loves the organ they specialize in more than nephrologists love the kidney
Unedited love song for the kidneys during #nephjc party #kidneywk
All the applause go to @Maximal_Change
Joshua Waitzman, MD PhD retweeted
A little piece of history-l from @NYUnephro Homer Smith’s PH meter -probably the most significant PH meter in neph history
Joshua Waitzman, MD PhD retweeted
"We do much more complicated things, we use much more dangerous drugs for other conditions that don't deliver like this"
"And if you don't do it, you're likely to become obsolete... because someone else will"
Professor Tuttle with a #kidneywk call to arms 🔥🔥🔥 #kidneycompass
Replying to @RealPatCampbell
Last but certainly not least, Tuttle on FLOW and nephrology’s role in prescribing GLP-1s in kidney disease:
hcplive.com/view/kidney-comp…
Joshua Waitzman, MD PhD retweeted
Let’s make the @ISNkidneycare campaign #KidneyHealth a global priority a success!
nephjc.com/news/isn-who-peti…
#NephJC #KidneyWk
Joshua Waitzman, MD PhD retweeted
I also left mid-career during an exciting moment (I’d just moved the lab and was just ramping up in a stimulating new environment that was a stellar scientific fit). So swapping jobs/sectors at the time was a lot more pull than push.
But while I was doing my job exactly as I wanted, I was still putting one foot in front of the other on what felt like a pre-determined trajectory.
IMO, a totally valid reason to change course is to look anew at the world as it is today (frankly right now feels like the most exciting time in science in my lifetime), and actively re-evaluate whether you still want to be on the path you decided on 10+ years ago.
I think it’s ok to keep opting into our lives. That way even if we keep doing what we’re doing, it’s on purpose.
Why Are Successful Scientists Leaving Academia Mid-Career? the-scientist.com/why-are-su…
Joshua Waitzman, MD PhD retweeted
Big congrats #H3AfricaKDRN consortium for this landmark paper nejm.org/doi/full/10.1056/NE…. Take home message APOL1 HR genotype as high as 50% in some Afr pop, 1 risk variant assoc with CKD. Thanks @NIDDKgov #NHGRI, @NIH for supporting this program
DAPA-advKD trialing the initiation of SGLT2i in CKD4 and CKD5!
The next frontier of #flozination. #kidneywk
At baseline, both groups had fairly high UACr, ~700 mg/g, an average eGFR 19.
Slopes of both groups slowed after enrollment (?regression to mean), and slowed more for SGLT2! #kidneywk
And all the secondary outcomes are in favor of SGLT2i!
Is this a huge enough trial to prove this is 100% effective? No, we’re still going to wait for renal lifecycles.
But is it strong data that Sglt2s don’t accelerate progression and might help?
Yes! #flozinate #kidneywk
Thanks @jaykoyner for this great slide. The figure is key. #kidneywk
You can whisper sweet nothings to salt as much as you like.
They are just nothings
#kidneywk
(Not really true—we can still identify people w high risk of badness. Maybe SGLT2is would reduce badness?
Also h/t @Julie_Celine: pubmed.ncbi.nlm.nih.gov/3201… )
FLOW outcomes by CKD stage are being reported by @KatherineTuttl8
Gotta plug the great @FreelyFiltered episode with @VladoPerkovic and @brendonneuen nephjc.com/freelyfiltered/20… #kidneywk
This figure will always make me smile; semaglutide saves kidneys.
Subgroup analyses show no heterogeneity by GFR or albuminuria.
#kidneywk






















